Osteosarcoma Clinical Trials 2022
Osteosarcoma studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect osteosarcoma clinical trial in 2022.
Condition
Osteosarcoma
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
Osteosarcoma Clinical Trials 2022
Phase-Based Estimates
1
Effectiveness
1
Safety
UB_TT170
for Sarcoma
Seattle, WA
< 65
All Sexes
Phase 1
Recruiting
Metastatic
Seattle, WA
< 65
All Sexes
The purpose of this study is to see if a new treatment could help patients who have osteosarcoma that does not go away with treatment (is refractory) or comes back after treatment (is recurrent).This study is testing a combination of study therapies, UB-TT170 and genetically modified chimeric antigen receptor T lymphocyte (CAR T) cells, which work together in a way that is different from chemotherapy. In this study, researchers will take some of your blood and remove the T cells in a process called "apheresis". Then the T cells are taken to a lab and changed to CAR T cells that recognize the flags from UB-TT170. Once researchers think they have grown enough CAR T cells, called antiFL(FITC-E2) CAR T cells, to fight your cancer, you may get some chemotherapy to make room in your body for the new cells and then have those cells put back in your body. A few days after the you get your CAR T cell infusion you will start to get infusions of UB-TT170, with the dose slowly increasing for the first few infusions until you have reached a maximum dose that you will get on a regular schedule. The UB-TT170 will attach to your tumor cells and flag them so that they attract the CAR T cells. When the CAR T cells see the labeled tumor cells they can kill the tumor cells. The active part of the study lasts about 8 months, and if you get the CAR T cell infusion you will be in long-term follow-up for 15 years.
Phase-Based Estimates
1
Effectiveness
2
Safety
Cryoablation Therapy
for Cancer
Washington, United States
< 65
All Sexes
Phase 2
Recruiting
Metastatic
Washington, United States
< 65
All Sexes
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult patients with relapsed or refractory solid tumors.
Phase-Based Estimates
2
Effectiveness
3
Safety
Thoracotomy
for Cancer
Valhalla, NY
< 65
All Sexes
Phase 3
Recruiting
Metastatic
Valhalla, NY
< 65
All Sexes
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
Phase-Based Estimates
1
Effectiveness
1
Safety
ZN-c3
for Osteosarcoma
Nashville, TN
Any Age
All Sexes
Phase 1 & 2
Recruiting
Metastatic
Nashville, TN
Any Age
All Sexes
This study is evaluating whether a combination of two drugs may help treat osteosarcoma.
Phase-Based Estimates
1
Effectiveness
2
Safety
Nivolumab
for Osteosarcoma
Minneapolis, MN
Any Age
All Sexes
Phase 2
Recruiting
Class I
Minneapolis, MN
Any Age
All Sexes
This study is evaluating whether a combination of two drugs may help treat osteosarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Second Generation 4-1BBζ B7H3-EGFRt-DHFR(selected) And A Second Generation 4-1BBζ CD19-Her2tG
for Cancer
Seattle, WA
< 65
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Seattle, WA
< 65
All Sexes
This study is evaluating whether genetically modified T cells may be able to
Phase-Based Estimates
1
Effectiveness
2
Safety
Ceralasertib
for Osteosarcoma
Boston, MA
< 65
All Sexes
Phase 2
Recruiting
Metastatic
Boston, MA
< 65
All Sexes
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: Olaparib Ceralasertib
Phase-Based Estimates
1
Effectiveness
2
Safety
Abemaciclib
for Osteosarcoma
Jacksonville, FL
18+
All Sexes
Phase 2
Recruiting
Metastatic
Jacksonville, FL
18+
All Sexes
This study is evaluating whether a drug may help treat sarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Glucarpidase
for Osteosarcoma
Rochester, MN
18+
All Sexes
Phase < 1
Recruiting
Newly Diagnosed
Rochester, MN
18+
All Sexes
This study is evaluating whether a drug which breaks down methotrexate, a common chemotherapy drug, may help reduce the side effects of chemotherapy.
Phase-Based Estimates
1
Effectiveness
1
Safety
Losartan
for Osteosarcoma
Aurora, CO
< 65
All Sexes
Phase 1
Recruiting
Metastatic
Aurora, CO
< 65
All Sexes
This study is evaluating whether a combination of two medications may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
IC9.GD2.CAR.IL-15 T-cells
for Osteosarcoma
Chapel Hill, NC
< 65
All Sexes
Phase 1
Recruiting
High Risk
Chapel Hill, NC
< 65
All Sexes
The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. Antibodies work by sticking to those bacteria or substances, which stops them from growing and causing bad effects. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been enough to cure most patients. This study is designed to combine both T cells and antibodies in order to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9), also known as iC9.GD2.CAR.IL-15 T cells. In previous studies, it has been shown that when T cells have part of an antibody attached to them they are better at recognizing and killing cancer cells. The antibody that will be used in this study is called anti-GD2. This antibody floats around in the blood and can detect and stick to cancer cells called neuroblastoma cells because they have a substance on the outside of the cells called GD2. For this study, the anti-GD2 antibody has been changed so instead of floating freely in the blood, it is now joined to the T cells. However, it is unknown how long the iC9.GD2.CAR.IL-15 T cells last in the body, so their chances of fighting cancer cells are not well known. To improve the tumor fighting power of GD2-CAR-T cells, our researchers have added two additional components to these cells. The IL-15 gene was added so that the GD2-CAR-T cells can attack tumor cells more effectively. Interleukin-15 (IL-15) is a chemical that cells use to communicate with one another. Other research using IL-15 in combination with CAR-T cells has shown there is an increase in the body's ability to allow the CAR-T cells to survive and grow in the body. The iC9 gene was added as an "off switch" so it can stop the activity of the GD2-CAR-T cells if you experience any serious bad side effects. Bad side effects seen previously in patients receiving the GD2 antibody alone include pain. In this study, the "stop switch" can be used to turn off the GD2-CAR-T cells if you experience intense pain that does not respond to normal pain treatments. The primary purpose of this study is to determine whether receiving iC9.GD2.IL-15 T cells is safe and tolerable in patients with relapsed/refractory neuroblastoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Post Treatment Surgery
for Osteosarcoma
Saint Petersburg, FL
< 65
All Sexes
Phase 1 & 2
Recruiting
Metastatic
Saint Petersburg, FL
< 65
All Sexes
This study is evaluating whether a combination of two drugs may help treat osteosarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Second Generation 4-1BBζ EGFR806-EGFRt And A Second Generation 4 1BBζ CD19-Her2tG
for Cancer
Seattle, WA
< 65
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Seattle, WA
< 65
All Sexes
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a EGFR-specific receptor (chimeric antigen receptor, or CAR) that will target and kill solid tumors that express EGFR and the selection-suicide marker EGFRt. EGFRt is a protein incorporated into the cell with our EGFR receptor which is used to identify the modified T cells and can be used as a tag that allows for elimination of the modified T cells if needed. On Arm A of the study, research participants will receive EGFR-specific CAR T cells only. On Arm B of the study, research participants will receive CAR T cells directed at EGFR and CD19, a marker on the surface of B lymphocytes, following the hypothesis that CD19+ B cells serving in their normal role as antigen presenting cells to T cells will promote the expansion and persistence of the CAR T cells. The CD19 receptor harbors a different selection-suicide marker, HERtG. The primary objectives of the study will be to determine the feasibility of manufacturing the cell products, the safety of the T cell product infusion, to determine the maximum tolerated dose of the CAR T cells products, to describe the full toxicity profile of each product, and determine the persistence of the modified cell in the subject's body on each arm. Subjects will receive a single dose of T cells comprised of two different subtypes of T cells (CD4 and CD8 T cells) felt to benefit one another once administered to the research participants for improved potential therapeutic effect. The secondary objectives of this protocol are to study the number of modified cells in the patients and the duration they continue to be at detectable levels. The investigators will also quantitate anti-tumor efficacy on each arm. Subjects who experience significant and potentially life-threatening toxicities (other than clinically manageable toxicities related to T cells working, called cytokine release syndrome) will receive infusions of cetuximab (an antibody commercially available that targets EGFRt) or trastuzumab (an antibody commercially available that targets HER2tG) to assess the ability of the EGFRt on the T cells to be an effective suicide mechanism for the elimination of the transferred T cell products.
Phase-Based Estimates
1
Effectiveness
1
Safety
CLR 131
for Cancer
Toronto, Canada
< 65
All Sexes
Phase 1
Recruiting
Metastatic
Toronto, Canada
< 65
All Sexes
This study is evaluating whether a drug called CLR 131 may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
CB-103
for Hematologic Neoplasms
Houston, TX
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a drug called CB-103 may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Diffusion Weighted Magnetic Resonance Imaging
for Sarcoma
Memphis, TN
Any Age
All Sexes
Waitlist Available
Metastatic
Memphis, TN
Any Age
All Sexes
Children with sarcomas are routinely assessed with a variety of imaging techniques that involve the use of ionizing radiation. These include computed tomography (CT), nuclear bone scan, and positron emission tomography-CT (PET-CT). Pediatric sarcoma patients undergo many imaging studies at the time of diagnosis, during therapy and for years following completion of therapy. Because children are in a stage of rapid growth, their tissues and organs are more susceptible to the harmful effects of ionizing radiation than are adults. Furthermore, compared to adults, children have a longer life expectancy and, therefore, a longer period of time in which to develop the adverse sequelae of radiation exposure, such as the development of second malignancies. Alternative experimental methods of measuring tumor response will be compared to current standard of care measures to determine if the experimental method is equivalent to methods currently being used. Investigators wish to determine if they can reduce patient's exposure to the harmful effects of ionizing radiation by replacing imaging studies that use radiation with whole body diffusion weighted magnetic resonance imaging (DW-MRI) which does not use any radiation. They also want to know if DW-MRI measurements of the tumor can tell how well the tumor is responding to therapy. There have been studies in adults with cancer that have shown that DW-MRI provides useful information about how tumors are responding to therapy. There have only been very small studies of DW-MRI in children with tumors in the body. Therefore, the role of DW-MRI in pediatric sarcoma patients is not yet known and it is still experimental. This study might give us important information that could help us treat other children with bone or soft tissue sarcomas in the future.
Phase-Based Estimates
1
Effectiveness
1
Safety
Guided Therapy
for Astroblastoma
Charlotte, NC
< 65
All Sexes
Waitlist Available
High Risk
Charlotte, NC
< 65
All Sexes
This study is evaluating whether a new technology can be used to determine the molecular makeup of a tumor.
Phase-Based Estimates
1
Effectiveness
2
Safety
Donor NK Cell Infusion
for Sarcoma
Milwaukee, WI
Any Age
All Sexes
Phase 2
Waitlist Available
Grade III
Milwaukee, WI
Any Age
All Sexes
This study is evaluating whether a cellular and adoptive immunotherapy approach can improve disease control rate for people with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Magnetic Resonance High Intensity Focused Ultrasound
for Cancer
Washington, United States
< 65
All Sexes
Phase 1
Waitlist Available
1 Prior Treatment
Washington, United States
< 65
All Sexes
This study is evaluating whether a new type of surgery may be effective for treating tumors in children and young adults.
Phase-Based Estimates
1
Effectiveness
1
Safety
MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Cyclophosphamide
for Relapse
Dallas, TX
< 65
All Sexes
Phase 1
Recruiting
Locally Advanced
Dallas, TX
< 65
All Sexes
This study is evaluating whether a combination of two drugs may help treat certain types of cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
GD2 T Cells
for Sarcoma
Houston, TX
Any Age
All Sexes
Phase 1
Waitlist Available
High Risk
Houston, TX
Any Age
All Sexes
This study is evaluating whether a new gene can be put into T cells that will make them recognize and kill sarcoma and neuroblastoma cells.
Phase-Based Estimates
1
Effectiveness
1
Safety
Metronomic Cyclophosphamide
for Spongioblastoma
Saint Louis, MO
< 65
All Sexes
Phase 1
Recruiting
Saint Louis, MO
< 65
All Sexes
This study is evaluating whether two drugs may help prevent tumors from growing after stem cell transplant.
Phase-Based Estimates
1
Effectiveness
2
Safety
Methionine
for Cancer
Memphis, TN
Any Age
All Sexes
Phase 2
Recruiting
Grade I
Memphis, TN
Any Age
All Sexes
This study is evaluating whether a radioactive form of an amino acid may help doctors better understand and treat tumors.
Phase-Based Estimates
1
Effectiveness
1
Safety
Tissue Procurement
for Osteosarcoma
New York, NY
Any Age
All Sexes
Waitlist Available
New York, NY
Any Age
All Sexes
This study is evaluating whether tumors in the laboratory respond differently to different drugs.
Phase-Based Estimates
1
Effectiveness
1
Safety
Surufatinib In Combination With Gemcitabine
for Sarcoma
Orange, CA
< 65
All Sexes
Phase 1 & 2
Recruiting
Grade I
Orange, CA
< 65
All Sexes
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts.
Phase-Based Estimates
1
Effectiveness
2
Safety
18-F FTC 146
for Osteosarcoma
Stanford, CA
18+
All Sexes
Phase 2
Recruiting
Newly Diagnosed
Stanford, CA
18+
All Sexes
This study is evaluating whether a new imaging agent may help doctors better evaluate whether a tumor is responding to treatment.
Phase-Based Estimates
3
Effectiveness
3
Safety
Enoxaparin 40Mg/0.4mL Prefilled Syringe
for Venous Thromboembolism
Boston, MA
18+
All Sexes
Phase 4
Waitlist Available
High Risk
Boston, MA
18+
All Sexes
This study is evaluating whether aspirin or low molecular weight heparin is better at preventing deep vein thrombosis (DVT) after orthopaedic surgery.
Phase-Based Estimates
1
Effectiveness
2
Safety
Olaparib
for Histiocytosis
Tacoma, WA
< 65
All Sexes
Phase 2
Waitlist Available
Locally Advanced
Tacoma, WA
< 65
All Sexes
This study is evaluating whether olaparib may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Larotrectinib Sulfate
for Central Nervous System Neoplasms
West Palm Beach, FL
< 65
All Sexes
Phase 2
Recruiting
Grade II
West Palm Beach, FL
< 65
All Sexes
This study is evaluating whether a drug called larotrectinib may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Samotolisib
for Pulmonary Histiocytosis X
Mesa, AZ
< 65
All Sexes
Phase 2
Recruiting
Grade II
Mesa, AZ
< 65
All Sexes
This study is evaluating whether a drug called samotolisib may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Tazemetostat
for Central Nervous System Neoplasms
Portland, OR
< 65
All Sexes
Phase 2
Waitlist Available
Grade II
Portland, OR
< 65
All Sexes
This study is evaluating whether tazemetostat is effective in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come back (relapsed) or do not respond to
Phase-Based Estimates
1
Effectiveness
2
Safety
Ensartinib
for Germ Cell Cancer
Madera, CA
< 65
All Sexes
Phase 2
Recruiting
Locally Advanced
Madera, CA
< 65
All Sexes
This study is evaluating whether a drug may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Larotrectinib
for Recurrent Osteosarcoma
Minneapolis, MN
< 65
All Sexes
Phase 2
Recruiting
Locally Advanced
Minneapolis, MN
< 65
All Sexes
This study is evaluating whether genetic testing may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Phase-Based Estimates
1
Effectiveness
2
Safety
Avelumab
for Osteosarcoma
New York, NY
< 65
All Sexes
Phase 2
Waitlist Available
Metastatic
New York, NY
< 65
All Sexes
This study is evaluating whether a drug called avelumab can help treat osteosarcoma in children.
Phase-Based Estimates
1
Effectiveness
2
Safety
Nab-Paclitaxel
for Sarcoma, Ewing
Los Angeles, CA
< 65
All Sexes
Phase 2
Recruiting
Grade I
Los Angeles, CA
< 65
All Sexes
This study is evaluating whether a combination of two chemotherapy drugs may help treat children with certain types of cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Doxorubicin
for Sarcoma
Toronto, Canada
< 65
All Sexes
Phase 1
Waitlist Available
Metastatic
Toronto, Canada
< 65
All Sexes
This study is evaluating whether chemotherapy delivered directly to the lungs at the time of surgery is safe and effective.
Phase-Based Estimates
1
Effectiveness
1
Safety
Abemaciclib
for Rhabdoid Tumor
Atlanta, GA
< 65
All Sexes
Phase 1
Recruiting
Grade III
Atlanta, GA
< 65
All Sexes
This study is evaluating whether a drug may help treat brain tumors.
Phase-Based Estimates
1
Effectiveness
1
Safety
Magnetic Resonance High Intensity Focused Ultrasound
for Neuroblastoma
Washington, United States
< 65
All Sexes
Phase 1
Recruiting
1 Prior Treatment
Washington, United States
< 65
All Sexes
This study is evaluating whether a combination of a drug and a focused ultrasound may be effective for treating children with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Zoledronate
for Leukemia
Madison, WI
< 65
All Sexes
Phase 1
Recruiting
Class I
Madison, WI
< 65
All Sexes
This study is evaluating whether a transplant of white blood cells from a close relative may help leukemia patients recover following chemotherapy.
Phase-Based Estimates
1
Effectiveness
2
Safety
GM-CSF
for Osteosarcoma
New York, NY
< 65
All Sexes
Phase 2
Recruiting
1 Prior Treatment
New York, NY
< 65
All Sexes
This study is evaluating whether an antibody and a drug may help prevent relapse of a disease.
Phase-Based Estimates
1
Effectiveness
2
Safety
Nivolumab
for Sarcoma
Las Vegas, NV
18+
All Sexes
Phase 2
Waitlist Available
Grade I
Las Vegas, NV
18+
All Sexes
This study is evaluating whether a combination of nivolumab and ipilimumab is more effective than nivolumab alone in treating patients with sarcoma that has spread from the primary site to other parts of the body (metastatic) or cannot be removed by surgery (
Phase-Based Estimates
1
Effectiveness
2
Safety
Dinutuximab
for Osteosarcoma
Burlington, VT
< 65
All Sexes
Phase 2
Waitlist Available
Grade II
Burlington, VT
< 65
All Sexes
This study is evaluating whether dinutuximab works better when given with sargramostim in treating patients with osteosarcoma that has come back after treatment.
Phase-Based Estimates
1
Effectiveness
2
Safety
Denosumab
for Osteosarcoma
Hamilton, Canada
< 65
All Sexes
Phase 2
Waitlist Available
Metastatic
Hamilton, Canada
< 65
All Sexes
This study is evaluating whether denosumab is effective in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory).
Phase-Based Estimates
1
Effectiveness
1
Safety
Lenvatinib
for Osteosarcoma
Houston, TX
< 65
All Sexes
Phase 1 & 2
Waitlist Available
Metastatic
Houston, TX
< 65
All Sexes
This study is evaluating whether lenvatinib is safe and effective in children and adolescents with refractory or relapsed solid malignancies.
Phase-Based Estimates
1
Effectiveness
1
Safety
Real-Time CEUS
for Sarcoma
Los Angeles, CA
18+
All Sexes
Phase < 1
Waitlist Available
Los Angeles, CA
18+
All Sexes
This study is evaluating whether real-time contrast-enhanced ultrasonography and shear wave elastography can predict treatment response in patients with soft tissue sarcomas.
Phase-Based Estimates
1
Effectiveness
1
Safety
Pharmacological Study
for Recurrent Neuroblastoma
Milwaukee, WI
< 65
All Sexes
Phase 1 & 2
Waitlist Available
Metastatic
Milwaukee, WI
< 65
All Sexes
This study is evaluating whether a combination of nivolumab and ipilimumab is safe and effective in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory).
Phase-Based Estimates
1
Effectiveness
2
Safety
Doxorubicin
for Sclerosing Epithelioid Fibrosarcoma
Rochester, NY
Any Age
All Sexes
Phase 2 & 3
Waitlist Available
Grade II
Rochester, NY
Any Age
All Sexes
This study is evaluating whether a combination of radiation therapy and chemotherapy with or without pazopanib is better than radiation therapy alone in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Phase-Based Estimates
1
Effectiveness
1
Safety
Aerosolized Aldesleukin
for Cancer
Houston, TX
< 65
All Sexes
Phase 1
Waitlist Available
Grade I
Houston, TX
< 65
All Sexes
This study is evaluating whether aerosolized aldesleukin is safe and effective in treating patients with cancer that has spread to the lungs.
Phase-Based Estimates
2
Effectiveness
3
Safety
Methotrexate
for Osteosarcoma
Los Angeles, CA
< 65
All Sexes
Phase 3
Waitlist Available
Metastatic
Los Angeles, CA
< 65
All Sexes
This study is evaluating whether a combination of chemotherapy and interferon alfa-2b is more effective than two different combination chemotherapy regimens alone in treating osteosarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Copper Gluconate
for Sarcoma
Cleveland, OH
Any Age
All Sexes
Phase 1
Waitlist Available
Grade I
Cleveland, OH
Any Age
All Sexes
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Phase-Based Estimates
1
Effectiveness
2
Safety
Cabozantinib
for Osteosarcoma
Houston, TX
Any Age
All Sexes
Phase 2
Waitlist Available
Grade I
Houston, TX
Any Age
All Sexes
This study is evaluating whether atezolizumab and cabozantinib are safe and effective in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body
Phase-Based Estimates
1
Effectiveness
2
Safety
OST31-164
for Osteosarcoma
Baltimore, MD
< 65
All Sexes
Phase 2
Recruiting
Grade II
Baltimore, MD
< 65
All Sexes
This study is evaluating whether a drug called OST31-164 can help prevent lung cancer from coming back.
Phase-Based Estimates
1
Effectiveness
1
Safety
Ascorbate
for Sarcoma
Iowa City, IA
< 18
All Sexes
Phase < 1
Waitlist Available
Locally Advanced
Iowa City, IA
< 18
All Sexes
This study is evaluating whether a combination of vitamin C and chemotherapy may be effective in treating sarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Magrolimab
for Osteosarcoma
Vancouver, Canada
< 65
All Sexes
Phase 1
Recruiting
Class II
Vancouver, Canada
< 65
All Sexes
This study is evaluating whether a combination of two monoclonal antibodies can shrink or stabilize relapsed or refractory neuroblastoma or relapsed osteosarcoma.
Phase-Based Estimates
1
Effectiveness
2
Safety
Oleclumab
for Osteosarcoma
Houston, TX
Any Age
All Sexes
Phase 2
Recruiting
Metastatic
Houston, TX
Any Age
All Sexes
This study is evaluating whether a drug called oleclumab and a drug called durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has
Phase-Based Estimates
1
Effectiveness
1
Safety
Cabozantinib
for Sarcoma, Ewing
Boston, MA
< 65
All Sexes
Phase 1
Recruiting
Class III
Boston, MA
< 65
All Sexes
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. The names of the drugs are: Cabozantinib Topotecan Cyclophosphamide The names of the non-investigational supportive care drugs are: Filgrastim, pegfilgrastim, or a related growth factor.
Phase-Based Estimates
1
Effectiveness
1
Safety
Ascorbate
for Sarcoma
Iowa City, IA
18+
All Sexes
Phase < 1
Recruiting
Locally Advanced
Iowa City, IA
18+
All Sexes
This study is evaluating whether a drug called pembrolizumab may help treat sarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
GD2-CAR-expressing Autologous T-lymphocytes
for Osteosarcoma
Madison, WI
< 65
All Sexes
Phase 1
Recruiting
Grade I
Madison, WI
< 65
All Sexes
This study is evaluating whether a new type of immune cell therapy called GD2CART is safe and effective in treating patients with osteosarcoma or neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory).
Phase-Based Estimates
1
Effectiveness
2
Safety
Selpercatinib
for Histiocytosis
Lebanon, NH
< 65
All Sexes
Phase 2
Recruiting
Locally Advanced
Lebanon, NH
< 65
All Sexes
This study is evaluating whether a drug may help treat certain types of cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Tipifarnib
for Spongioblastoma
Ann Arbor, MI
< 65
All Sexes
Phase 2
Recruiting
Grade II
Ann Arbor, MI
< 65
All Sexes
This study is evaluating whether a drug called tipifarnib may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Ivosidenib
for Spongioblastoma
Los Angeles, CA
< 65
All Sexes
Phase 2
Recruiting
Grade II
Los Angeles, CA
< 65
All Sexes
This study is evaluating whether a drug may help treat children with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Chemotherapy (gemcitabine & Docetaxel) Plus BIO-11006
for Osteosarcoma
Miami, FL
< 65
All Sexes
Phase 2
Recruiting
Locally Advanced
Miami, FL
< 65
All Sexes
This study is evaluating whether a drug may help treat lung metastases in children with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Metastasectomy
for Sarcoma
Buffalo, NY
18+
All Sexes
Phase 1 & 2
Recruiting
Metastatic
Buffalo, NY
18+
All Sexes
This study is evaluating whether a drug called cisplatin can be delivered to the lungs to treat sarcomas that have spread to the lungs.
Phase-Based Estimates
1
Effectiveness
1
Safety
Humanized 3F8 Bispecific Antibody
for Neuroblastoma
New York, NY
< 18
All Sexes
Phase 1 & 2
Recruiting
Stage III
New York, NY
< 18
All Sexes
This study is evaluating whether a new drug may be safe for individuals with cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Natalizumab
for Pulmonary Metastatic Osteosarcoma (pOS)
Cleveland, OH
< 65
All Sexes
Phase 1 & 2
Recruiting
Grade I
Cleveland, OH
< 65
All Sexes
The purpose of this study is to evaluate the safety and tolerability of Natalizumab in children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS) and to assess clinical response associated with this treatment as well as overall survival.
Phase-Based Estimates
1
Effectiveness
2
Safety
Ulixertinib
for Central Nervous System Neoplasms
Peoria, IL
< 65
All Sexes
Phase 2
Waitlist Available
Locally Advanced
Peoria, IL
< 65
All Sexes
This study is evaluating whether ulixertinib is effective in treating children with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic
Phase-Based Estimates
1
Effectiveness
1
Safety
C7R-GD2.CART Cells
for Sarcoma
Houston, TX
Any Age
All Sexes
Phase 1
Recruiting
Locally Advanced
Houston, TX
Any Age
All Sexes
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Because there is no standard treatment at this time, patients are asked to volunteer in a gene transfer research study using special immune cells called T cells. T cells are a type of white blood cell that helps the body fight infection. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise but have not been strong enough to cure most patients. We have found from previous research that we can put a new gene into T cells that will make them recognize cancer cells and kill them. In our last clinical trial we made a gene called a chimeric antigen receptor (CAR) from an antibody that recognizes GD2, a substance found on almost all neuroblastoma cells (GD2-CAR). We put this gene into the patients' own T cells and gave them back to 11 neuroblastoma patients. We saw that the cells did grow for a while, but started to disappear from the blood after 2 weeks. We think that if T cells are able to last longer they may have a better chance of killing GD2 positive tumor cells. Therefore, in this study we will add a new gene to the GD2 T cells that can cause the cells to live longer. T cells need substances called cytokines to survive and the cells may not get enough cytokines after infusion. We have added the gene C7R that gives the cells a constant supply of cytokine and helps them to survive for a longer period of time. In other studies using T cells, investigators found that giving chemotherapy before the T cell infusion can improve the amount of time the T cells stay in the body and therefore the effect the T cells can have. This is called lymphodepletion and we think that it will allow the T cells to expand and stay longer in the body, and potentially kill cancer cells more effectively. The GD2-C7R T cells are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the largest safe dose of GD2-C7R T cells, and also to evaluate how long they can be detected in the blood and what affect they have on cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Hydroxychloroquine
for Osteosarcoma
Houston, TX
Any Age
All Sexes
Phase 1 & 2
Waitlist Available
Metastatic
Houston, TX
Any Age
All Sexes
This study is evaluating whether a combination of chemotherapy drugs and hydroxychloroquine may be effective in treating osteosarcoma.
Phase-Based Estimates
1
Effectiveness
2
Safety
Pegylated Arginine Deiminase
for Sarcoma
Santa Monica, CA
Any Age
All Sexes
Phase 2
Waitlist Available
Grade II
Santa Monica, CA
Any Age
All Sexes
This study is evaluating whether a drug that depletes arginine in tumors can improve the effect of gemcitabine in patients with sarcomas.
Phase-Based Estimates
1
Effectiveness
2
Safety
Autologous Tumor Infiltrating Lymphocytes LN-145
for Malignancy in Giant Cell Tumor of Bone
Houston, TX
Any Age
All Sexes
Phase 2
Recruiting
Metastatic
Houston, TX
Any Age
All Sexes
This study is evaluating whether a specific type of white blood cell may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Pepinemab
for Osteosarcoma
Ann Arbor, MI
< 65
All Sexes
Phase 1 & 2
Waitlist Available
Metastatic
Ann Arbor, MI
< 65
All Sexes
This study is evaluating whether pepinemab is safe and effective in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment.
Phase-Based Estimates
1
Effectiveness
1
Safety
GRID Radiotherapy
for Osteosarcoma
Little Rock, AR
< 65
All Sexes
Recruiting
Metastatic
Little Rock, AR
< 65
All Sexes
This study is evaluating whether a higher dose of radiation may be more effective for treating osteosarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Gemcitabine
for Neoplasm Metastasis
Houston, TX
< 65
All Sexes
Phase 1
Recruiting
Metastatic
Houston, TX
< 65
All Sexes
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have spread to the lungs from other parts of the body. The safety and side effects of this drug will also be studied. This is an investigational study. Gemcitabine is FDA approved and commercially available for the treatment of pancreatic and lung cancer, and other solid tumors. Its administration by inhalation is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.
Phase-Based Estimates
1
Effectiveness
1
Safety
FACT Complex-targeting Curaxin CBL0137
for Metastatic Malignant Neoplasm in the Central Nervous System
Cincinnati, OH
< 65
All Sexes
Phase 1 & 2
Recruiting
Grade II
Cincinnati, OH
< 65
All Sexes
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Phase-Based Estimates
1
Effectiveness
1
Safety
Tegavivint
for Melanoma
Boston, MA
< 65
All Sexes
Phase 1 & 2
Recruiting
Metastatic
Boston, MA
< 65
All Sexes
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Phase-Based Estimates
1
Effectiveness
2
Safety
Lenvatinib
for Osteosarcoma
Hackensack, NJ
< 65
All Sexes
Phase 2
Waitlist Available
1 Prior Treatment
Hackensack, NJ
< 65
All Sexes
This study is evaluating whether a drug called lenvatinib may help treat osteosarcoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Supportive Care
for Disease Progression
Fullerton, CA
18+
All Sexes
Waitlist Available
Locally Advanced
Fullerton, CA
18+
All Sexes
This study is evaluating whether a health care coach can help reduce acute care use and cost in people with cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Stereotactic Body Radiation Therapy (SBRT)
for Bone Diseases